Health Affairs August 25, 2023
Troyen A. Brennan, William H. Shrank

So rare is bipartisan regulatory legislation in Congress, especially in health care, that when it occurs one must presume it is in response to prohibitive costs to society or a threat to patient welfare. Pharmacy benefit managers (PBMs) seem to be considered both, as no fewer than eight separate bills to change PBM practices have recently been introduced or advanced out of committee, all of them involving both Democratic and Republican co-sponsors. This remarkable collaboration, following on the heels of the historic, and decidedly partisan, decision to allow the Centers for Medicare and Medicaid Services (CMS) to negotiate medication prices, deserves careful policy analysis.

Pharmacy Benefit Management Tools And Strategies

PBMs are a relatively new addition to the health policy...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: CMS, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech, Regulations
Eli Lilly to invest $27B in manufacturing
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
Lilly expands US manufacturing build-out with $50B target
How AI Drug Manufacturing Is Changing the Game

Share This Article